Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs

July 27, 2010 at 12:03 pm Leave a comment

J. Antimicrob. Chemother. August 2010  V.65  N.8  p.1784-1791

Jason A. Crompton1, Donald S. North1, MinJung Yoon1, Judith N. Steenbergen1, Kenneth C. Lamp1,* and Graeme N. Forrest2

1 Cubist Pharmaceuticals, 65 Hayden Ave, Lexington, MA 02421, USA 2 Portland VA Medical Center, 3701 SW US Veterans Hospital Rd, P3-ID, Portland, OR 97239, USA

Objectives

Recent recommendations by the Infectious Diseases Society of America for the treatment of Staphylococcus aureus suggest the use of alternative agents when vancomycin MIC values are 2 mg/L. This study examines the outcome of patients treated with daptomycin for S. aureus infections with documented vancomycin MICs.

Patients and methods

All patients with skin, bacteraemia and endocarditis infections due to S. aureus with vancomycin MIC values in CORE 2005–08, a retrospective, multicentre, observational registry, were studied. The outcome (cure, improved, failure or non-evaluable) was the investigator assessment at the end of daptomycin therapy. Success was defined as cure or improved.

Results

Five hundred and forty-seven clinically evaluable patients were identified with discrete vancomycin MIC values [MIC <2 mg/L: 451 (82%); MIC 2 mg/L: 96 (18%)]. The vancomycin MIC groups were well matched for patient characteristics, types of infections, first-line daptomycin use (19%) and prior vancomycin use (58%). Clinical success was reported in 94% of patients. No differences were detected in the daptomycin success rate by the vancomycin MIC group overall or by the infection type. A multivariate logistic regression also failed to identify vancomycin MIC as a predictor of daptomycin failure. Adverse event (AE) rates were not different when analysed by MIC group; both groups had 17% of patients with one AE.

Conclusions

In this diverse population, daptomycin was associated with similar outcomes for patients, regardless of whether the vancomycin MIC was categorized as <2 or 2 mg/L. Further studies are warranted.

abstract

http://jac.oxfordjournals.org/cgi/content/abstract/65/8/1784?etoc

PDF

http://jac.oxfordjournals.org/cgi/reprint/65/8/1784

Entry filed under: Antimicrobianos, Bacterias, Bacteriemias, Resistencia bacteriana.

A rifampicin-containing antibiotic treatment improves outcome of staphylococcal deep sternal wound infections Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

Trackback this post  |  Subscribe to the comments via RSS Feed


Calendar

July 2010
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  

Most Recent Posts


%d bloggers like this: